|1.||Kano, Makoto: 2 articles (04/2008 - 03/2005)|
|2.||Omori, Koichi: 2 articles (04/2008 - 03/2005)|
|3.||Miura, Tomohiro: 2 articles (04/2008 - 03/2005)|
|4.||Matsuzuka, Takashi: 2 articles (04/2008 - 03/2005)|
|5.||Kuwano, Hiroyuki: 2 articles (04/2006 - 09/2003)|
|6.||Endo, Keigo: 2 articles (04/2006 - 09/2003)|
|7.||Asao, Takayuki: 2 articles (04/2006 - 09/2003)|
|8.||Oriuchi, Noboru: 2 articles (04/2006 - 09/2003)|
|9.||Igci, Abdullah: 1 article (04/2008)|
|10.||Eroglu, Aylin: 1 article (04/2008)|
04/29/2002 - "There are assumed to be three general classes of susceptibility of the malaria parasite Plasmodium falciparum to a drug: Res0, the original, susceptible wildtype; Res1, a group of intermediate levels of susceptibility that are more tolerant of the drug but still cleared by treatment; and Res2, which is completely resistant to the drug. "
07/01/1999 - "In this study, the suitability of [188Re]rhenium sulfide suspension for tumor treatment following intra-tumor injection was evaluated. "
06/01/2007 - "The small-sized rhenium sulfide nanoparticles may be useful for their promising applications in tracing diagnosis and therapy of tumor diseases."
09/01/2003 - "The day before surgery, technetium-99m colloidal rhenium sulfide was injected into the submucosa at four sites around the primary tumor. "
05/01/2000 - "The retention percentages of radioactivity (%ID) in tumors injected with [(188)Re]rhenium sulfide suspension were 90.96+/-6.63%, 86.09+/-22.58% and 87.62+/-13.97% at 1, 24 and 48 h, respectively. "
05/01/2000 - "Another 30 tumor-bearing mice were divided into six groups, four groups of which were treated with a 0.1 ml [(188)Re]rhenium sulfide suspension at doses of 3.7, 7.4, 18.5, 29.6 MBq by a single intratumoral injection. "
04/01/2006 - "Sentinel lymph node mapping with technetium-99m colloidal rhenium sulfide in patients with gastric carcinoma."
09/01/2003 - "Sentinel lymph nodes with technetium-99m colloidal rhenium sulfide in patients with esophageal carcinoma."
05/01/2000 - "Intratumoral injection with [(188)Re]rhenium sulfide suspension for treatment of transplanted human liver carcinoma in nude mice."
05/01/2000 - "Intratumoral injection of [(188)Re]rhenium sulfide suspension results in high tumor retention indicating this approach has strong potential for the treatment of hepatic carcinoma."
05/01/2000 - "Thirty nude mice bearing SMMC 7721 human liver carcinoma were used for the biodistribution study after intratumoral injection of [(188)Re]rhenium sulfide suspension or sodium [(188)Re]perrhenate solution. "
|4.||Stomach Neoplasms (Stomach Cancer)
|2.||Hanks Balanced Salt Solution
|3.||perrhenate (rhenium oxide)
|4.||Technetium (Technetium 99m)
|9.||DNA (Deoxyribonucleic Acid)
|2.||Drug Therapy (Chemotherapy)